Dengue vaccine candidate proves efficacious in preventing any of the four serotypes of the virus
by Press Release from Outbreak News Today on (#481ZC)
Takeda Pharmaceutical Company Limited today announced that the pivotal Phase 3 trial of its dengue vaccine candidate met the primary efficacy endpoint. This first analysis of the Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial showed that the company's investigational live-attenuated tetravalent dengue vaccine (TAK-003) was efficacious in preventing dengue fever caused by any of the four serotypes ["]
The post Dengue vaccine candidate proves efficacious in preventing any of the four serotypes of the virus appeared first on Outbreak News Today.